Table 4 The ORR, mTTSP of patients who received two or more lines of chemotherapy before PARPi maintenance therapy based on BRCA status in the PS group
PFI ≥ 6 months | 6 ≤ PFI < 12 months | PFI ≥ 12 months | ||||
|---|---|---|---|---|---|---|
ORR (%) | mTTSP (95%CI) (month) | ORR (%) | mTTSP (95%CI) (month) | ORR (%) | mTTSP (95%CI) (month) | |
BRCA mutations (n = 7) | 57.1 | 18.0 (5.0–31.0) | 50 | 19.0 (17.5–19.5) | 60 | 10.5 (3.2–18.8) |
BRCA wild–type (n = 28) | 42.9 | 8.0 (4.9–11.1) | 45.5 | 7.4 (5.5–8.5) | 41.2 | 10.5 (4.6–15.4) |
Total (n = 35) | 45.7 | 10.0 (4.9–15.2) | 46.2 | 10.2 (5.6–14.4) | 45.5 | 10.5 (4.8–15.2) |